CAS 85721-33-1|Ciprofloxacin
Introduction：Basic information about CAS 85721-33-1|Ciprofloxacin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Ciprofloxacin | ||
|---|---|---|---|
| CAS Number | 85721-33-1 | Molecular Weight | 331.341 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 581.8±50.0 °C at 760 mmHg |
| Molecular Formula | C17H18FN3O3 | Melting Point | 255-257°C |
| MSDS | ChineseUSA | Flash Point | 305.6±30.1 °C |
Names
| Name | ciprofloxacin |
|---|---|
| Synonym | More Synonyms |
Ciprofloxacin BiologicalActivity
| Description | Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity. |
|---|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>BacterialResearch Areas >>Infection |
| In Vitro | Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1]. Ciprofloxacin (CIP) shows potent activity against Y. pestis with MIC90 of 0.03 μg/mL[2]. |
| In Vivo | Ciprofloxacin (1 mg/L) induces glutathione-S-transferase (GST) activity, in contrast with inhibited GST and Catalase (CAT) of larvae exposed to enrofloxacin. Ciprofloxacin (≥10 μg/L) and enrofloxacin are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes in anuran amphibian larvae[1]. In a murine model of pneumonic plague, Ciprofloxacin (30 mg/kg, i.p.) results in a drug exposure which is similar to the drug exposure observed in human following a 500 mg dose of oral Ciprofloxacin. Intraperitoneal Ciprofloxacin reduces the lung bacterial load compare to controls treated with intraperitoneal PBS[3]. |
| Cell Assay | Bacterial inocula are prepared by suspending colonies into Mueller-Hinton broth (CAMHB) (containing Ciprofloxacin) from 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) on sheep blood agar (SBA) plates that are incubated at 35°C. Suspended cultures are diluted with CAMHB to a bacterial cell density of 105 CFU/mL adjusted based on the optical density at 600 nm. To each well of the 96-well plate, 50 μL of dilutions is added for a final inoculum of ~5×104 CFU/well. Plates are incubated at 35°C. MICs are determined visually at 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) and also by absorbance at 600 nm[2]. |
| Animal Admin | Female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old and 20 g (±4 g) are used in this assay. A single dose of Ciprofloxacin (30 mg/kg) is administered to mice (n=30) via the intraperitoneal (i.p.) route. The mice (n=3/time point/group) are culled at 1, 10, 20, or 30 min and 1, 1.5, 2, 4, 8, 12 h following Ciprofloxacin administration and 1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI or CFI administration. Blood sampling points are chosen based upon the short half-life of Ciprofloxacin and longer half-life of CFI. Blood and lungs (whole organ) are collected post mortem for analysis. The lung doses following CFI or DRCFI administration are calculated using the concentration of Ciprofloxacin in the lung samples at 1 min post-administration[3]. |
| References | [1]. Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4. pii: S1382-6689(17)30029-7 [2]. Steenbergen J, et al. In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Feb 21. [3]. Hamblin KA, et al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 581.8±50.0 °C at 760 mmHg |
| Melting Point | 255-257°C |
| Molecular Formula | C17H18FN3O3 |
| Molecular Weight | 331.341 |
| Flash Point | 305.6±30.1 °C |
| Exact Mass | 331.133209 |
| PSA | 74.57000 |
| LogP | 0.65 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.655 |
| InChIKey | MYSWGUAQZAJSOK-UHFFFAOYSA-N |
| SMILES | O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O |
| Storage condition | Store at 0-5°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 21429 ug/kg/3D-I
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions Behavioral - toxic psychosis
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 21 mg/kg/3D-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - urine volume decreased Kidney, Ureter, Bladder - proteinuria Kidney, Ureter, Bladder - hematuria
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 5714 ug/kg/2D-I
- TOXIC EFFECTS :
- Behavioral - coma Liver - jaundice, other or unclassified Liver - liver function tests impaired
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 129 mg/kg/6D-I
- TOXIC EFFECTS :
- Behavioral - rigidity (including catalepsy)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 135 mg/kg/3D-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 40 mg/kg/2D-I
- TOXIC EFFECTS :
- Behavioral - headache Blood - eosinophilia Nutritional and Gross Metabolic - body temperature increase
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Multiple routes
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 40 mg/kg/6D-I
- TOXIC EFFECTS :
- Skin and Appendages - dermatitis, allergic (after systemic exposure) Skin and Appendages - dermatitis, other (after systemic exposure)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >1 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 207 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1165 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >1 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 122 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)
- TYPE OF TEST :
- Cytogenetic analysis
- TYPE OF TEST :
- Sister chromatid exchange
MUTATION DATA - TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Mammal - domestic Cells - not otherwise specified
- DOSE/DURATION :
- 27 mg/L
- REFERENCE :
- AMACCQ Antimicrobial Agents and Chemotherapy. (American Soc. for Microbiology, 1913 I St., NW, Washington, DC 20006) V.1- 1972- Volume(issue)/page/year: 34,1955,1990
- TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Mammal - domestic Cells - not otherwise specified
- DOSE/DURATION :
- 27 mg/L
- REFERENCE :
- AMACCQ Antimicrobial Agents and Chemotherapy. (American Soc. for Microbiology, 1913 I St., NW, Washington, DC 20006) V.1- 1972- Volume(issue)/page/year: 34,1955,1990
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | VB1993800 |
| HS Code | 3004909090 |
Customs
| HS Code | 3004909090 |
|---|
Articles896
More Articles| A short splice form of Xin-actin binding repeat containing 2 (XIRP2) lacking the Xin repeats is required for maintenance of stereocilia morphology and hearing function. J. Neurosci. 35(5) , 1999-2014, (2015) Approximately one-third of known deafness genes encode proteins located in the hair bundle, the sensory hair cell's mechanoreceptive organelle. In previous studies, we used mass spectrometry to charac... | |
| NADPH oxidase expression and production of superoxide by human corneal stromal cells. Mol. Vis. 15 , 2535-43, (2009) Superoxide (O(2) (.-)) may function as a second messenger or regulator of signal transduction when produced at low concentrations in the proper locations within cells. The purpose of these studies was... | |
| Genotypes and oxacillin resistance of Staphylococcus aureus from chicken and chicken meat in Poland. Poult. Sci. 93(12) , 3179-86, (2014) The genotypes and oxacillin resistance of 263 Staphylococcus aureus isolates cultured from chicken cloacae (n = 138) and chicken meat (n = 125) was analyzed. Fifteen spa types were determined in the s... |
Synonyms
| CPFX |
| ciproiv |
| CIPROBAY |
| euciprin |
| Cipro |
| Ciprine |
| ciloxan |
| Ciprofloxacin |
| Cipmbay |
| ciprobid |
| Baycip |
| MFCD00185755 |
